Ketim Therapeutics Welcomes Dr. Scott Fry, Ph.D., to Advisory Board

Brisbane, Australia – January 30, 2025 – Ketim Therapeutics (“Ketim Therapeutics Pty Ltd”), a leading innovator in perinatal mental health solutions, is proud to announce the appointment of Dr. Scott Fry, Ph.D., to its Advisory Board. Dr. Fry brings decades of expertise in biotechnology and diagnostics, further strengthening Ketim’s mission to pioneer biomarker-based innovations for women’s health.

Dr. Fry’s distinguished career spans leadership roles across multinational pharmaceutical and biotechnology organizations in both Australia and the United States. In his most recent position as Chief Operations Officer at Ellume Limited, he played a pivotal role in the development, manufacturing, and commercialization of diagnostic tests, including the successful launch of the first over-the-counter COVID-19 diagnostic test in the United States.

In addition to his contributions to COVID-19 diagnostics, Dr. Fry has extensive experience leading projects for rapid diagnostic tests and ELISAs to detect Dengue, Influenza A and B, Group A Streptococcus, Respiratory Syncytial Virus, and other diseases.

A Ph.D. graduate in immunology from the University of Southern Queensland, Dr. Fry began his career in research at the University of Queensland, where he developed a strong foundation in life sciences innovation. His impressive background in diagnostics and commercial strategy aligns perfectly with Ketim Therapeutics’ vision to advance perinatal mental health through cutting-edge biomarker research and diagnostics.

“We are delighted to welcome Dr. Scott Fry to our Advisory Board,” said Dr. Clarissa Yates, CEO of Ketim Therapeutics. “Scott’s unparalleled expertise in diagnostics and product commercialization will be instrumental as we continue to push boundaries in women’s mental health and wellness. His strategic insights will greatly contribute to our mission of improving perinatal outcomes and transforming care through science-driven solutions.”

Dr. Fry’s appointment comes as Ketim Therapeutics accelerates its efforts to launch biomarker-based screening tools and predictive analytics platforms for perinatal mental health, including postpartum depression.

For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Therapeutics
clarissa.yates@ketim.com.au